• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Crit Care . Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and

tetano

Editor, Senior Moderator
J Crit Care


. 2023 Nov 15:79:154463.
doi: 10.1016/j.jcrc.2023.154463. Online ahead of print. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism

M Raadsen[SUP] 1 [/SUP], T Langerak[SUP] 1 [/SUP], J Du Toit[SUP] 2 [/SUP], M J H A Kruip[SUP] 3 [/SUP], D Aynekulu Mersha[SUP] 4 [/SUP], M de Maat[SUP] 3 [/SUP], B Vermin[SUP] 5 [/SUP], J P C Van den Akker[SUP] 6 [/SUP], K S Schmitz[SUP] 1 [/SUP], K Bakthiari[SUP] 7 [/SUP], J C Meijers[SUP] 7 [/SUP], E C M van Gorp[SUP] 1 [/SUP], K R Short[SUP] 8 [/SUP], B Haagmans[SUP] 1 [/SUP], R D de Vries[SUP] 1 [/SUP], D A M P J Gommers[SUP] 6 [/SUP], H Endeman[SUP] 6 [/SUP], M Goeijenbier[SUP] 9 [/SUP]; Dutch COVID & Thrombosis Coalition



Affiliations
Abstract

Purpose: Pulmonary emboli (PE) contribute substantially to coronavirus disease 2019 (COVID-19) related mortality and morbidity. Immune cell-mediated hyperinflammation drives the procoagulant state in COVID-19 patients, resulting in immunothrombosis. To study the role of peripheral blood mononuclear cells (PBMC) in the procoagulant state of COVID-19 patients, we performed a functional bioassay and related outcomes to the occurrence of PE. Secondary aims were to relate this functional assay to plasma D-dimer levels, ventilation perfusion mismatch and TF expression on monocyte subsets.
Methods: PBMC from an ICU biobank were obtained from 20 patients with a computed tomography angiograph (CTA) proven PE and compared to 15 COVID-19 controls without a proven PE. Functional procoagulant properties of PBMC were measured using a modified fibrin generation time (MC-FGT) assay. Tissue factor (TF) expression on monocyte subsets were measured by flow cytometry. Additional clinical data were obtained from patient records including end-tidal to arterial carbon dioxide gradient.
Results: MC-FGT levels were highest in the samples taken closest to the PE detection, similar to the end-tidal to arterial carbon dioxide gradient (ETCO2 - PaCO2), a measurement to quantify ventilation-perfusion mismatch. In patients without proven PE, peak MC-FGT relates to an increase in end-tidal to arterial carbon dioxide gradient. We identified non-classical, CD16 positive monocytes as the subset with increased TF expression.
Conclusion: We show that the procoagulant state of PBMC could aid in early detection of PE in COVID-19 ICU patients. Combined with end-tidal to ETCO2 - PaCO2 gradient, these tests could improve early detection of PE on the ICU.

Keywords: COVID-19; Immunothrombosis; Pulmonary embolism; SARS-CoV-2; Tissue factor.

 
Back
Top Bottom